6 March 2021

General assembly

Cardiac Amyloidosis: A Tantalizing Topic Reimagined (ATTR)

✓ RIZIV/INAMI accreditation requested (N° 20022019; category: 3)[1]

✓ FANC/AFCN radiation protection continuing education: 1.0 hour for nuclear medicine physicians

✓ Venue: Virtual only

Program

Moderators: Dr. Jeroen Mertens (AZ Maria Middelares, Ghent)

9:00-9:45 *General assembly*
BELNUC Board

9:45-10:00 *Break*

10:00-10:30 *Clinical aspects of cardiac amyloidosis*
Prof. dr. Steven Droogmans (UZ Brussels)

10:30-11:00 *Diagnosis of cardiac amyloidosis*
Prof. dr. Olivier Gheysens (UC Louvain)

11:00-11:15 *Break*

11:15-11:30 *Organizing multi-disciplinary care in cardiac amyloidosis*
Prof. dr. Steven Droogmans (UZ Brussels) and Prof. dr. Olivier Gheysens (UC Louvain)

11:30-12:00 *Case presentation*
Moderator: Dr. Jeroen Mertens (AZ Maria Middelares, Ghent)
Panelists: Prof. dr. Steven Droogmans (UZ Brussels) and Prof. dr. Olivier Gheysens (UC Louvain)

12:00-12:30 *Q&A*

Supported by:

Pfizer

[1] RIZIV/INAMI accreditation for nuclear medicine physicians is available for BELNUC members only.

BELNUC - Belgian Society of Nuclear Medicine | Avenue Hippocrate 10, 1200 Brussels, Belgium
BELNUC Office: c/o EANM - Schmalzhofgasse 26 - Top 5, 1060 Vienna, Austria
SBMN ASBL - BGVNG VZW Nr.: 418.553.416

Seminar cardiac transthyretin amyloidosis

Cardiac amyloidosis of transthyretin fibril protein (ATTR) type is an infiltrative cardiomyopathy characterized by ventricular wall thickening and diastolic heart failure. Improved awareness and advances in diagnosis have led to a marked increase in patients with wild-type ATTR (senile systemic) amyloidosis and Afro-Caribbean patients with the hereditary ATTR V122I type. Both subtypes present predominantly as isolated cardiomyopathy. The differential diagnosis includes cardiac amyloid light-chain (AL) amyloidosis, which has a poorer prognosis and can be amenable to chemotherapy. This seminar targets physicians that are involved in the diagnosis and treatment of ATTR, including nuclear medicine physicians and cardiologists. The presentations will familiarize the attendees with the clinical features of cardiac ATTR amyloidosis and describe the diagnostic tests to determine ATTR type. A correct diagnosis is ever more crucial, given that several novel therapies for ATTR amyloidosis have become available.

1) Refresh the epidemiology and pathophysiology of cardiac amyloidosis with a focus on ATTR.
2) Present the clinical manifestations and treatment options for ATTR.
3) Discuss the diagnosis of ATTR, with a focus on the use of radionuclide imaging.
4) Present best-practice examples of establishing a multidisciplinary care pathway for ATTR patients
5) Engage interactive discussion using case examples

The recent introduction of effective therapies for ATTR have led to an increased importance in the correct diagnosis of this condition. There is currently a need for imaging specialists to become aware of this condition and how to appropriately perform and interpret the diagnostic imaging studies. Moreover, there is a need for improved collaboration between clinical and imaging specialists in order not to miss patients with ATTR.

BELNUC - Belgian Society of Nuclear Medicine | Avenue Hippocrate 10, 1200 Brussels, Belgium
BELNUC Office: c/o EANM - Schmalzhofgasse 26 - Top 5, 1060 Vienna, Austria
SBMN ASBL - BGVNG VZW Nr.: 418.553.416